The feasibility of fluoroscopically guided percutaneous gastrostomy in patients with cystic fibrosis is presented, highlighting differences between these and other patients undergoing the procedure.
Methods
Six patients with cystic fibrosis referred for FGPG from November 1991 to May 1992 were prospectively studied. The referral criteria were body weight <80% of ideal, and failure to improve with dietary counselling and oral supplements. All patients had pancreatic insufficiency.
Before the procedure pulmonary function was optimised by chest physiotherapy. All patients fasted overnight and had a nasogastric tube inserted. During the procedure the patient lay on a fluoroscopy table. The stomach was distended with air via the nasogastric tube. An entry site in the left hypochondrium was infiltrated with local anaesthetic and the stomach was then punctured with a Jelco 16 gauge 152 mm sheathed needle (Critikon). The needle was withdrawn and a 0 097 cm Lunderquist Ring torque guidewire (Cook) was introduced through the sheath and coiled in the stomach. The tract was dilated and the gastrostomy tube then introduced over the guidewire. An 8 French pigtail nephrostomy catheter (Cook) was used. This catheter has a loop at the end which facilitates retention within the gastric lumen.
Following gastrostomy patients ate normally by day. Using a pump, a peptide feed (Reabilan HN, Roussel) of 1000-1500 calories was delivered during the night via the gastrostomy. Patients took oral enzymes -for example, Nutrizym (E Merck Pharmaceuticals) 4-8 capsules -before and after each feed.
Results
There were four men and two women of mean age 26 6 years. The nutritional and respiratory status of the patients is outlined in table 1. Tube placement was successful in all patients, low dose sedation being necessary in four cases. After the procedure five patients experienced pain at the gastrostomy site which required narcotic analgesia. Satisfactory feeding rates (60-175 ml/hour) were attained in all tubes. Two patients subsequently required tube replacement for dislodgement and leakage respectively. Other problems included a case of gastro-oesophageal reflux which resolved spontaneously, and a gastrostomy site infection which responded to antibiotic therapy. Meconium ileus equivalent developed two days after the procedure in two patients (in whom there was a prompt response to treatment) and after two months in a third (in whom the response to treatment was poorer).
Four of the patients died of their underlying condition within 111 days of FGPG. In all cases tube function was maintained until the time of death or review, representing an average follow up of 20 8 weeks.
Details of nutritional and respiratory status before, at the time of, and after the procedure are outlined in table 2.
Discussion
In this small series we established and maintained a functioning gastrostomy tube in all cases until the time of review or death. No major complications were encountered, and the incidence of minor complications such as tube dislodgement, leakage, and infection is similar to that among our other gastrostomy cases'0 and following surgical enterostomy in patients with cystic fibrosis. '6 However, a number of differences were noted between this group and other patients in whom we have performed FGPG.'°Firstly, We have documented the nutritional and pulmonary status after the procedure for completeness, but our numbers are too small to be meaningful.
In conclusion, our results show the feasibility of enteral feeding by FGPG in patients with cystic fibrosis. This, in our opinion, is the procedure of choice for long term enteral feeding in these patients, particularly those with advanced disease. We also highlight differences between patients with cystic fibrosis and others undergoing FGPG. 
